TheProfitWatch

GILD - Gilead Sciences Inc

Day 1m 10m 60m PreMarket Market AfterHours Gap
118.31 0.52 (0.44%) --- --- --- -0.59 (-0.5%) 0.26 (0.22%) 0.33 (0.28%) 0.33 (0.28%)

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Closed

Earnings & Ratios

Basic EPS:
1.57
Diluted EPS:
1.56
Basic P/E:
75.6879
Diluted P/E:
76.1731
RSI(14) 1m:
0.0
VWAP:
118.87
RVol:
0.4568

Events

Period Kind Movement Occurred At

Related News